Clinical trials can collect thousands of medical scans across different hospitals. Turning those images into consistent evidence is often slower and more difficult than collecting them.
Qureight has raised $20 million in Series B funding, led by Molten Ventures. Existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension also participated.
The Cambridge-based company provides imaging services and AI-powered measurements for lung and heart clinical trials. Its platform helps pharmaceutical companies manage scans, measure structural changes and create more precise endpoints for evaluating whether a treatment is working.
Founded by Dr. Muhunthan Thillai, Co-founder and CEO, and Dr. Alessandro Ruggiero, Co-founder and CSO. The company already works across fibrotic lung-disease trials, where small changes in medical images can help research teams understand disease progression and treatment response.
The new funding will support a dedicated AI imaging laboratory built around Qureight’s 3D chest-imaging foundation model. The company expects this infrastructure to reduce the data and development time required to create imaging tools for additional diseases.
Qureight plans to expand into asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity, while continuing its work in lung fibrosis. It will also grow its commercial team as demand increases from pharmaceutical and biotechnology companies.
The round also brings Dr. Inga Deakin of Molten Ventures and Anna Salim of Hargreave Hale onto Qureight’s board. Their appointments add healthcare investment and scaling experience as the company enters new disease areas.
Qureight is part of a wider shift toward AI-supported clinical trials, where medical scans are becoming measurable data rather than records reviewed only through manual processes.
